This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

BioMarin Announces Positive Final Results for Vosoritide - Phase 3


16th Dec 2019

BioMarin reported positive final results from the Phase 3 clinical trial evaluating the efficacy and safety of vosoritide (BMN 111) in children with achondroplasia. 
The placebo-adjusted change from baseline in growth velocity after one year of treatment with vosoritide, the primary endpoint, was 1.6 cm/yr (p<0.0001). The study enrolled 121 children aged 5 to 14 with achondroplasia. The results were consistent across the broad patient population studied.  Vosoritide was generally well tolerated with no clinically significant blood pressure decreases.1
 

The primary endpoint of the study is the change in growth velocity from baseline over one year in children treated with vosoritide compared to placebo. A wide range of secondary and exploratory endpoints include anthropometric measures such as height Z-score, body and limb proportionality and joint geometry; biochemical, biomarker and radiological assessments of bone growth and health; and evaluations of health-related quality of life (HRQoL), developmental status, and functional independence. 
These additional endpoints address the overall impact vosoritide has on achondroplasia and will continue to be evaluated in an ongoing open-label extension study where all subjects receive active treatment.2


BMN111 2Figure 1. BioMarin R&D Day - 14th November 2019

Based on the results, BioMarin plans to have pre-submission meetings with Health Authorities Planned for the first half of 2020 to discuss Marketing Applications for Market authorization.

EUPATI stages market authorization

Figure 2. Marketing Authorisation Applications, EUPATI

  

 

Medicines development process is a long journey. The ultimate goal of any development process of a new medicinal product, as vosoritide, is market approval, called Marketing Authorisation (MA).3 

A market application is an application submitted by a drug manufacturer/pharma company seeking permission to bring a medicinal product (for example, a new medicine or generic medicine) to the market. The main Health Authorities are EMA (Europe), FDA (USA) and PDMA (Japan)

Market Application Authorization (MAA) is part of the official procedure before the Committee for Medicinal Products for Human Use of the European Commission. In the USA, the equivalent process is called New Drug Application, conducted by FDA.

So, if vosoritide development keeps being positive, there is still a long process before it becomes available for children outside the clinical trial. And it may not become available in all countries but only in those BioMarin submits a market application. 

Resources:
1. BioMarin - Placebo-controlled phase 3 vosoritide
2. Seeking Alfa
3. EUPATI - Marketing Authorisation ApplicationsMarketing Authorisation Applications

 
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.